Back to discover

Protein / target

Large ribosomal subunit protein uL6

Encoded byRPL9P32969Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
27
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Structural constituent of ribosome

Strongest disease association

Hemorrhoid

Via encoding gene RPL9 · Genetic evidence · score 0.23

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Component of the large ribosomal subunit.

View complete UniProt function annotation

Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547)

Subcellular location

Cytoplasm
Domains and Gene Ontology detail (18)

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Ccytosolic large ribosomal subunit
  • Ccytosolic ribosome
  • Cendoplasmic reticulum
  • Cfocal adhesion
  • Cmembrane
  • Cnucleolus
  • Cnucleus
  • Cribosome
  • FRNA binding
  • FrRNA binding

192 aa · 22 kDa

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Muscular Dystrophy, Duchenne1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

ataluren
ApprovedModulator

80S Ribosome modulator

Indicated for Muscular Dystrophy, Duchenne

Acts on a complex — shared with RPL24, RPL26, RPSA +74 more · 1 of 78 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene RPL9

Gene-level evidence surfaced through the gene RPL9that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Cystic Fibrosis
0.48Limited support

Clinical evidence dominant · Open Targets 0.39

Influenza, Human
0.30Preliminary

Pathway evidence dominant · Open Targets 0.46 · no direct causal or clinical evidence

Hemorrhoid
0.23Preliminary

Genetic evidence dominant · Open Targets 0.14

View evidence synthesis (3)
Cystic FibrosisLimited support
0.48
agreement 0.330.64
Clinical98%Literature2%

Open Targets aggregate 0.39 · 2 independent evidence families

Influenza, HumanPreliminary
0.30
agreement 0.080.53
Pathway100%

Open Targets aggregate 0.46 · 1 independent evidence family · no direct causal or clinical evidence

HemorrhoidPreliminary
0.23
agreement 0.110.35
Genetic100%

Open Targets aggregate 0.14 · 1 independent evidence family

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Influenza, Human0.46
Cystic Fibrosis0.39
Hemorrhoid0.14

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (5)
ZOLIMOMAB ARITOXPhase 2
ELX-02Phase 2
MT-3724Phase 2
CITATUZUMAB BOGATOXPhase 1
ATALURENApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (6)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandPR · Database UbiquitinationPR · Small Molecule BinderOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

27

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (23)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Withdrawn from market2025-03-28

    Market withdrawal: Translarna (EMA)

    ema · market · ema · via ataluren

  2. New publication2021-02-04
    Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.

    Annals of clinical and translational neurology · 2021 · 29 citations · Europe PMC · via ataluren

  3. New publication2014-05-15
    Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

    The Lancet. Respiratory medicine · 2014 · 259 citations · Europe PMC · via ataluren

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.